AstraZeneca led a $40m Series C venture capital round that will fund PhaseBio's Phase IIa clinical trials for drug candidates to treat diabetes and heart failure – two key areas of interest for the UK-based big pharma company.
PhaseBio's recently appointed CEO Jonathan Mow, who previously was chief business officer, said AstraZeneca has "an option to option" the...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
